{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T15:45:49Z","timestamp":1778946349198,"version":"3.51.4"},"reference-count":26,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2010,3,25]],"date-time":"2010-03-25T00:00:00Z","timestamp":1269475200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>The aim of the study was to assess the prevalence, predictors and patterns of genotypic resistance mutations in children after failure of World Health Organization\u2010recommended initial nonnucleoside reverse transcriptase inhibitor (NNRTI)\u2010based treatment regimens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We carried out a multicentre retrospective study of genotyping tests performed for all HIV\u2010infected children at eight paediatric centres in Thailand who experienced failure of NNRTI therapy at a time when virological monitoring was not routinely available.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>One hundred and twenty children were included in the study. Their median age (interquartile range) was 9.1 (6.8\u201311.0) years, the median duration of their NNRTI regimens was 23.7 (15.7\u201332.6) months, their median CD4 percentage was 12% (4\u201320%), and their median plasma HIV RNA at the time of genotype testing was 4.8 (4.3\u20135.2) log<jats:sub>10<\/jats:sub> HIV\u20101 RNA copies\/mL. The nucleoside reverse transcriptase inhibitor (NRTI) resistance mutations found were as follows: 85% of the children had M184V\/I, 23% had at least four thymidine analogue mutations, 12% had the Q151M complex, 5% had K65R, and 1% had the 69 insertion. Ninety\u2010eight per cent of the children had at least one NNRTI resistance mutation, and 48% had etravirine mutation\u2010weighted scores \u22654. CD4 percentage &lt;15% prior to switching regimens [odds ratio (OR) 5.49; 95% confidence interval (CI) 2.02\u201314.93] and plasma HIV RNA&gt;5\u2003log<jats:sub>10<\/jats:sub>\u2003copies\/mL (OR 2.46; 95% CI 1.04\u20135.82) were independent predictors of at least four thymidine analogue mutations, the Q151M complex or the 69 insertion.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In settings without routine viral load monitoring, second\u2010line antiretroviral therapy regimens should be designed assuming that clinical or immunological failure is associated with high rates of multi\u2010NRTI resistance and NNRTI resistance, including resistance to etravirine.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2010.00828.x","type":"journal-article","created":{"date-parts":[[2010,3,26]],"date-time":"2010-03-26T01:54:35Z","timestamp":1269568475000},"page":"565-572","source":"Crossref","is-referenced-by-count":25,"title":["HIV\u20101 drug resistance mutations in children after failure of first\u2010line nonnucleoside reverse transcriptase inhibitor\u2010based antiretroviral therapy"],"prefix":"10.1111","volume":"11","author":[{"given":"T","family":"Puthanakit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Jourdain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S","family":"Hongsiriwon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Suntarattiwong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Chokephaibulkit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V","family":"Sirisanthana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Kosalaraksa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W","family":"Petdachai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R","family":"Hansudewechakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U","family":"Siangphoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T","family":"Suwanlerk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Ananworanich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"on behalf of the HIV\u2010NAT 086 study team","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,9,3]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/510489"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1086\/423178"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.inf.0000091282.70253.5f"},{"key":"e_1_2_6_5_2","unstructured":"Working Group on Antiretroviral Therapy and Medical Management of HIV\u2010Infected Children.Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection February 23 2009. US Department of Health and Human Services. Available athttp:\/\/AIDSinfo.nih.gov\/(accessed 14 April 2009)."},{"key":"e_1_2_6_6_2","first-page":"506","article-title":"National expansion of antiretroviral treatment in Thailand, 2000\u20132007","volume":"50","author":"Chasombat S","year":"2009","journal-title":"program scale-up and patient outcomes"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2008.0180"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0b013e31814278c0"},{"key":"e_1_2_6_9_2","first-page":"83","article-title":"HIV\u20101 drug resistance mutations in children who failed non\u2010nucleoside reverse transcriptase inhibitor\u2010based antiretroviral therapy","volume":"40","author":"Sungkanuparph S","year":"2009","journal-title":"Southeast Asian J Trop Med Public Health"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1086\/510745"},{"key":"e_1_2_6_11_2","first-page":"3083","article-title":"Etravirine","volume":"9","author":"Jayaweera DT","year":"2008","journal-title":"the renaissance of non-nucleoside reverse transcriptase inhibitors"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1086\/597469"},{"key":"e_1_2_6_13_2","first-page":"29","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment\u2010experienced HIV\u20101\u2010infected patients in DUET\u20101","volume":"370","author":"Madruga JV","year":"2007","journal-title":"24-week results from a randomised, double-blind, placebo-controlled trial"},{"key":"e_1_2_6_14_2","first-page":"138","article-title":"Update of the drug resistance mutations in HIV\u20101","volume":"16","author":"Johnson VA","year":"2008","journal-title":"Top HIV Med"},{"key":"e_1_2_6_15_2","unstructured":"MascoliniM.Monogram devises weighted genotypic score to predict etravirine response. XVII International Drug Resistance Workshop Spain. June 2008. Available athttp:\/\/www.natap.org\/2008\/ResisWksp\/ResisWksp_31.htm"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200309050-00007"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.2217\/hiv.09.28"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijid.2007.10.008"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0b013e3181a458f9"},{"key":"e_1_2_6_20_2","doi-asserted-by":"crossref","unstructured":"PrasitsuebsaiW BowenA PangJ HespC KariminiaA SohnAH.Pediatric HIV Clinical Care Resources and Management Practices in Asia: A Regional Survey of the TREAT Asia Pediatric Network.AIDS Patient Care STDS2010 [Epub ahead of print].","DOI":"10.1089\/apc.2009.0224"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1086\/381784"},{"key":"e_1_2_6_22_2","first-page":"1127","article-title":"The public health approach to identify antiretroviral therapy failure","volume":"23","author":"Hosseinipour MC","year":"2009","journal-title":"high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0b013e3282f3cc35"},{"key":"e_1_2_6_24_2","unstructured":"KekitinwaA FriedmanD CoakleyE LieY GrazianoF.Profiling etravirine resistance in Ugandan children with extended failure of a NNRTI\u2010inclusive regimen as first line ART. Presented at16th Conference on Retroviruses and Opportunistic Infections. Montreal Canada February 8\u201311 2009 [Abstract 891]."},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.2174\/157016208785861230"},{"key":"e_1_2_6_26_2","first-page":"409","article-title":"Virological monitoring and resistance to first\u2010line highly active antiretroviral therapy in adults infected with HIV\u20101 treated under WHO guidelines","volume":"9","author":"Gupta RK","year":"2009","journal-title":"a systematic review and meta-analysis"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-0691.2008.02116.x"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2010.00828.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2010.00828.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T21:03:19Z","timestamp":1698699799000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2010.00828.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9,3]]},"references-count":26,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1468-1293.2010.00828.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2010.00828.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,9,3]]}}}